Floatz logo

ERIBULIN MONOMETHANESULFONATE

Metastatic Breast Cancer ( HER2 Negative)

Eisai Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Metastatic Breast Cancer ( HER2 Negative) cohort.

Asset / SponsorPhaseRating
Ivonescimab
Fudan University
Phase 2CCC
Sacituzumab Tirumotecan
Fudan University
Phase 2CCC
Tucatinib
Institut Curie
Phase 2CCC
TRASTUZUMAB
Institut Curie
Phase 2CCC
Datopotamab Deruxtecan
Fudan University
Phase 2CCC

Same molecule, other indications

ERIBULIN MONOMETHANESULFONATE is also rated in:

breast neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
BB
Indicative ·
69 / 100
View asset →
Metastatic Triple-Negative Breast CarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →